- Home
- WHWK vs IMUX Comparison
WHWK vs IMUX Comparison
Compare WHWK & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WHWK | IMUX |
|---|---|---|
| Founded | 2007 | 2016 |
| Country | United States | United States |
| Employees | 22 | 66 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.8M | 152.6M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | WHWK | IMUX |
|---|---|---|
| Price | $3.39 | $1.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $7.00 | $4.80 |
| AVG Volume (30 Days) | 180.7K | ★ 2.1M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.39 | $0.51 |
| 52 Week High | $4.40 | $1.51 |
Technical Indicators
Market Signals| Indicator | WHWK | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 46.33 | 52.02 |
| Support Level | $1.84 | $1.05 |
| Resistance Level | $3.79 | $1.35 |
| Average True Range (ATR) | 0.24 | 0.10 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 33.58 | 45.31 |
Price Performance
Historical ComparisonAbout WHWK Whitehawk Therapeutics Inc.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.